A study led by a University of Manitoba researcher has brought science one step closer to using the chickenpox virus to develop a vaccine against HIV.
“Varicella-zoster virus, which causes chickenpox, may hold the key to inducing the human body to produce a safe, long-lasting, protective immune response to HIV,” said Dr. Kelly MacDonald, professor of internal medicine, immunology and medical microbiology at the U of M’s Max Rady College of Medicine and professor of immunology at the University of Toronto.
“Our study investigated an important safety concern that posed a barrier to this vaccine strategy. Now, with our findings, the stage is set to move forward with testing a chickenpox-based HIV vaccine.”
The study is the first in the world to demonstrate that chickenpox vaccine, when given to people who are already immune to it, does not trigger an unwanted “HIV-welcoming” immune state in the genital mucosa (lining) or in the bloodstream.
The study, Live-attenuated varicella-zoster virus vaccine does not induce HIV target cell activation, will be published in the Journal of Clinical Investigation and is now available online.
The project included researchers from the University of Toronto and the Kenyan AIDS Vaccine Initiative â Institute of Clinical Research at the University of Nairobi (Kenya). The U of M and the University of Nairobi have a long history of collaboration, dating back to 1980.
The study was supported by the Canadian Institutes of Health Research. Its lead author is Dr. Catia Perciani, a University of Toronto graduate student supervised by MacDonald.
MacDonald, head of the infectious diseases section in the U of M department of internal medicine, has worked in the field of host immunity to HIV and its application in vaccine design for more than 25 years. She sees potential in using the chickenpox virus in its vaccine form as a “vector” (carrier) to safely deliver HIV genes and generate immunity to HIV.
“A blended chickenpox/HIV vaccine would take advantage of the fact that chickenpox virus undergoes silent cycles of reactivation in the body. Each time it ‘wakes up’ from its dormant state, the body’s immunity quickly controls it, and the immunity is boosted,” MacDonald said.
“The idea is to combine what we call ‘HIV inserts’ with the chickenpox virus. We expect that each time the chickenpox virus is reactivated, it will also refresh immunity to HIV.”
Despite the promise of the vectored vaccine idea, MacDonald said, an international human clinical trial that used a different virus (adenovirus 5, or Ad5) as the vector for HIV genes was unsuccessful and had to be halted in 2007.
That vaccine had the unintended effect in people who were already immune to Ad5 of activating HIV “target cells” in mucosal surfaces, including the genital area. This may have increased their susceptibility to HIV infection.
The purpose of MacDonald’s study was to investigate whether chickenpox virus posed the same risk of this unwanted effect.
Her study was conducted in Kenya, a country severely affected by the HIV epidemic. The research participants were 44 healthy, HIV-negative women who were at low risk for HIV exposure and tested positive for immunity to chickenpox.
Researchers injected the women with a high-dose vaccine against only chickenpox virus. They tested each participant’s blood, as well as mucosal cells from her cervix and rectum, at intervals of four, eight and 12 weeks.
The key finding was that 12 weeks post-vaccination, there was no significant difference in the frequency of activated HIV target cells, compared to pre-vaccination.
The study also showed that the vaccine vigorously boosted the women’s existing immunity to chickenpox, not only in their bloodstream but in their genital area. This immune response in the genital area, where HIV infection first occurs, is a highly positive finding for the HIV vaccine concept.
“This chickenpox vaccine passed this comprehensive safety examination,” MacDonald said. “Our results pave the way for the use of chickenpox virus as a vector for HIV vaccine development.”
The next steps, the scientist said, are to continue testing the vaccine strategy using non-human primates and to start developing a chickenpox virus-vectored HIV vaccine for a clinical trial in humans.
Source: University of Manitoba
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.